Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IMM-6-415

Small molecule · Inhibitor of MEK (MAP2K1) · developed by Immuneering

Phase 1/2 Most advanced trial (none active)

IMRX Developer

1 Registered trials

What is IMM-6-415?

IMM-6-415 is an orally bioavailable small molecule deep cyclic inhibitor of MEK that blocks the RAS/RAF/MEK/ERK signaling pathway. It is being studied in advanced solid tumors, pancreatic adenocarcinoma, non-small cell lung cancer, and cutaneous melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: MEK (MAP2K1)
Mechanism: Inhibitor of MEK (MAP2K1)
Pathways: MAPK/ERK, RAS/RAF/MEK/ERK signaling
Therapy area: Oncology
Developer: Immuneering Corporation (IMRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06208124	Phase 1/2	Advanced Solid Tumor (Phase 1)	Completed	IMRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor (Phase 1)Malignant Melanoma (Cutaneous)Non-small Cell Lung CancerPancreas Adenocarcinoma

Other drugs acting on MAP2K1

Mirdametinib FDA approved Trametinib FDA approved Atebimetinib Phase 3 PAS-004 Phase 1

More from Immuneering

Atebimetinib Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IMRX page.

Follow IMRX, the company behind IMM-6-415

See IMRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z